About 400,000 people in Europe live with Pulmonary Fibrosis and some 100,000 patients die each year from the disease. The most common type of PF is IPF (Idiopathic Pulmonary Fibrosis), accounting for 200,000 patients in Europe. EU-IPFF, the European Patient organization presently runs the “Breathing Life” campaign to raise awareness of the disease and encourages spread of the campaign. Oxcia is happy to share.
New peer-reviewed article in Biomolecules, enforces the cancer cell selective killing of OXC-101. In a recently published article, Oxcia and its collaborators at Karolinska institute, shows that OXC-101 is extra efficacious in cancer cells overexpressing c-Myc (Hendriksson et al, Biomolecules… Continue reading New article enforces the cancer cell selective killing of OXC-101
Oxcia’s CEO Ulrika Warpman Berglund will attend the DDR Inhibitors Summit in Boston January 24-26th and present a poster describing the unique dual mechanism of action of OXC-101 and its potent and well tolerated anti-cancer effects. DDR is short for… Continue reading Oxcia attends DDR Inhibitors Summit in Boston
Tredje kvartalet (juli-september 2022) Rörelseresultatet uppgick till -10 927 043 (-3 573 590) SEK. Periodens resultat uppgick till -10 927 043 (-3 578 876) SEK. Kassaflödet från den löpande verksamheten uppgick till -4 612 924 (-2 749 079) SEK. Resultat per aktie före utspädning uppgick till -0,51… Continue reading Oxcia AB publicerar sin delårsrapport för tredje kvartalet 2022
